Transcript not yet available; please check back shortly.
The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.
VIDEO: Jupiter fixed income manager Ariel Bezalel says that falling inflation opens the door for ...
UPDATED: Here's what our analysts thought of Tesla, Meta, Alphabet, Apple, Amazon and Microsoft r...
We expect a better 2025 for Apple stock as the iPhone 16 launches with generative AI functionality
We take a deep dive into the prospects of Warren Buffett’s wide-moat behemoth ahead of Saturday's...
Morningstar has raised the fair value estimate for the Danish pharma stock, but shares are still ...
Mining companies are operating in a challenging environment but could now be the time to top up o...
THE WEEK: Morningstar columnist Rodney Hobson provides two pieces of advice to George Osborne, an...
Businesses that have competitive advantages within their industry are good candidates for dividen...
Morningstar reveals the top 10 best performers over the last five years
Morningstar OBSR reveals the top funds for investors seeking exposure to European equities
VIDEO: Jupiter fixed income manager Ariel Bezalel says that falling inflation opens the door for ...
UPDATED: Here's what our analysts thought of Tesla, Meta, Alphabet, Apple, Amazon and Microsoft r...
We expect a better 2025 for Apple stock as the iPhone 16 launches with generative AI functionality
We take a deep dive into the prospects of Warren Buffett’s wide-moat behemoth ahead of Saturday's...
Morningstar has raised the fair value estimate for the Danish pharma stock, but shares are still ...